Ï㽶ÊÓƵ

Journal Article

1. Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Galarza Fortuna G, Sayegh N, Tripathi N, Tandar C, Dal E, Li H, Swami U, Agarwal N, Maughan BL (2024). Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix. Ther Adv Urol, 16, 17562872241293779. ()
2. Iliopoulos O, Iversen AB, Narayan V, Maughan BL, Beckermann KE, Oudard S, Else T, Maranchie JK, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R, Jonasch E (2024). Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol, 25(10), 1325-1336. ()
3. Narang A, Gebrael G, Jo Y, Thomas VM, Li H, Fortuna GG, Sayegh N, Tandar C, Tripathi N, Chigarira B, Srivastava A, Hage Chehade C, Nordblad B, Maughan BL, Agarwal N, Swami U (2024). Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations. Kidney Cancer, 8(1), 135-142. ()
4. Fortuna GG, Chigarira B, Thomas VM, Sahu KK, Kumar SA, Tripathi N, Sayegh N, Agarwal N, Swami U, Maughan BL, Li H (2024). Clinical, Genomic, and Transcriptomic Characteristics of Patients with Metastatic Renal Cell Carcinoma Who Developed Thromboembolic Events. J Kidney Cancer VHL, 11(3), 13-22. ()
5. Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, Mathew Thomas V, Galarza Fortuna G, Narang A, Campbell P, Gupta S, Maughan BL, Roy S, Agarwal N, Swami U (2024). Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. JAMA Netw Open, 7(7), e2423186. ()
6. Luo MX, Lyle A, Bennett P, Albertson D, Sirohi D, Maughan BL, McMurtry V, Mahlow J (2024). Artificial intelligence chatbot vs pathology faculty and residents: Real-world clinical questions from a genitourinary treatment planning conference. Am J Clin Pathol. ()
7. Wiley HE, Srinivasan R, Maranchie JK, Chhablani J, Iversen ABB, Kruse A, Jonasch E, Gombos DS, Else T, Demirci H, Maughan BL, Hartnett ME, Coleman HR, Fu W, Perini RF, Liu Y, Linehan WM, Chew EY, LITESPARK-004 Investigator Group - Ocular VHL (2024). Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study. Ophthalmology. ()
8. Tripathi N, Gebrael G, Chigarira B, Sahu KK, Balasubramanian I, Caparas C, Mathew Thomas V, Cohan JN, Pelletier K, Maughan BL, Agarwal N, Swami U, Gupta S (2024). Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis. Cancers (Basel), 16(11). ()
9. Mathew Thomas V, Sayegh N, Chigarira B, Gebrael G, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami U (2024). Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy. Eur Urol Oncol. ()
10. Else T, Jonasch E, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Maranchie JK, Iversen AB, Goldberg CM, Fu W, Perini RF, Liu Y, Linehan WM, Srinivasan R (2023). Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clin Cancer Res, 30(9), 1750-1757. ()
11. Mathew Thomas V, Chigarira B, Gebrael G, Sayegh N, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami U (2024). Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI. JCO Precis Oncol, 8, e2300574. ()
12. Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal N (2024). Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. BMC Cancer, 24(1), 493. ()
13. Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan BL, Pal SK (2024). Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations. Eur Urol Focus. ()
14. Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, Srivastava A, Nordblad B, Dal E, Narang A, Brundage J, Campbell P, Galarza Fortuna G, Hage Chehade C, Maughan BL, Agarwal N, Swami U (2024). Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor. Cancer, 130(15), 2621-2628. ()
15. Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N (2024). Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting. Prostate, 84(9), 888-892. ()
16. Parikh M, Tangen C, Hussain MHA, Gupta S, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, Agarwal N (2024). Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. ()
17. Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, Agarwal N, Maughan BL (2024). A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). Oncologist, 29(5), 450-e725. ()
18. Miller EJ, Rose TL, Maughan BL, Milowsky MI, Bilen MA, Carthon BC, Gao X, Rapisuwon S, Zhao Q, Yu M, Agarwal N, Galsky MD (2024). Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade. Cancer. ()
19. Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL (2023). Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors. Urol Pract, 11(1), 101097UPJ0000000000000471. ()
20. Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL (2023). Reply by Authors. Urol Pract, 101097UPJ000000000000047102. ()
21. Li H, Sahu KK, Kumar SA, Tripathi N, Sayegh N, Nordblad B, Chigarira B, Gupta S, Maughan BL, Agarwal N, Swami U (2023). Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas. Cancers (Basel), 15(21). ()
22. Tripathi N, Thomas VM, Sayegh N, Gebrael G, Chigarira B, Jo Y, Li H, Sahu KK, Nussenzveig R, Nordblad B, Swami U, Agarwal N, Maughan BL (2023). Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer. Prostate, 83(16), 1602-1609. ()
23. Gebrael G, Sahu KK, Chigarira B, Tripathi N, Mathew Thomas V, Sayegh N, Maughan BL, Agarwal N, Swami U, Li H (2023). Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0. Cancers (Basel), 15(14). ()
24. Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N (2023). Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. Prostate Cancer Prostatic Dis. ()
25. Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan BL (2023). Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. Oncologist, 28(8), 737-e693. ()
26. McFarland TR, Mathew Thomas V, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, Agarwal N, Swami U (2022). Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting. Biomedicines, 10(12). ()
27. Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N (2022). External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer. Mol Cancer Ther, 21(12), 1857-1861. ()
28. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urol Oncol, 40(11), 493.e1-493.e7. ()
29. Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N, Barata PC (2022). Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist, 27(10), e815-e818. ()
30. Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N (2022). Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Front Oncol, 12, 966534. ()
31. Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami U (2022). A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon, 8(9), e10583. ()
32. Sonpavde GP, Maughan BL, McGregor BA, Wei XX, Kilbridge KL, Lee RJ, Yu EY, Schweizer MT, Montgomery RB, Cheng HH, Hsieh AC, Jain R, Grewal JS, Pico-Navarro C, Gafoor Z, Perschy T, Grivas P (2022). Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma. Cancer Immunol Immunother. ()
33. Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S (2022). Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol, 23, 899-909. ()
34. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Mndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators (2022). Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med, 386(12), 1132-1142. ()
35. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, MK-6482-004 Investigators (2021). Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med, 385(22), 2036-2046. ()
36. Swami U, Sinnott JA, Haaland B, Sayegh N, McFarland TR, Tripathi N, Maughan BL, Rathi N, Sirohi D, Nussenzveig R, Kohli M, Pal SK, Agarwal N (2021). Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. Cancers (Basel), 13(19). ()
37. Pal SK, McGregor B, Surez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N (2021). Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol, 39, JCO2100939. ()
38. Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK (2021). Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clin Cancer Res, 27(17), 4807-4813. ()
39. Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N (2021). Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist, 26(9), 751-760. ()
40. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N (2021). Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 26, 1006-e2129. ()
41. Maughan BL, Antonarakis ES (2021). Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. Expert Opin Pharmacother, 22(12), 1625-1632. ()
42. Brundage J, Maughan BL (2021). New models for defining prostate cancer biology and patient prognosis. Asian J Androl, 24, 119-120. ()
43. Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, Agarwal N (2020). Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. J Urol, 205(3), 709-717. ()
44. Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES (2020). Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 26(2), e270-e278. ()
45. McKay RR, McGregor BA, Xie W, Braun DA, Wei X, Kyriakopoulos CE, Zakharia Y, Maughan BL, Rose TL, Stadler WM, McDermott DF, Harshman LC, Choueiri TK (2020). Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol, 38(36), 4240-4248. ()
46. Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol, 78(5), 652-656. ()
47. Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, Asrani K, Alshalalfa M, Antonarakis ES, Epstein JI, Joshu CE, Schaeffer EM, Mosquera JM, Lotan TL (2020). Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate, 80(12), 1012-1023. ()
48. Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, ONeil B, Lowrance W (2020). 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urol Oncol, 38(7), 636.e1-636.e6. ()
49. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M (2020). Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res, 26(11), 2546-2555. ()
50. Rathi N, Maughan BL, Agarwal N, Swami U (2020). Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. Cancer Manag Res, 12, 3741-3749. ()
51. Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan BL (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res, 26(9), 2104-2110. ()
52. Maughan BL, Antonarakis ES (2020). Does sequencing order of antiandrogens in prostate cancer matter? Nat Rev Urol, 17(4), 197-198. ()
53. Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, Teerlink CC, Maughan BL, Feng BJ, Cannon-Albright L, Agarwal N, Cooney KA (2020). Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precis Oncol, 4. ()
54. Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N (2019). A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. Oncologist, 25(2), 121-e213. ()
55. Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M (2020). CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol, 4, 370-381. ()
56. Esther J, Dorff TB, Maughan BL (2020). Recent developments in the treatment of non-metastatic castration resistant prostate cancer. Cancer Treat Res Commun, 24, 100181. ()
57. Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, ONeil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C (2019). Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol, 37(33), 3090-3098. ()
58. Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N (2019). A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. Oncologist. ()
59. Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL (2019). Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. Drugs Aging, 36(5), 395-401. ()
60. Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N (2018). Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Mol Cancer Ther, 18(3), 726-729. ()
61. Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW (2019). Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Curr Treat Options Oncol, 20(2), 14. ()
62. Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N (2019). Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS One, 14(1), e0210415. ()
63. Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D, Agarwal N (2018). Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treat Res Commun, 19, 100116. ()
64. Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N (2019). Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treat Res Commun, 19, 100120. ()
65. Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, Agarwal N (2018). Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. Oncologist, 23(12), 1413-e151. ()
66. Sirohi D, Smith SC, Agarwal N, Maughan BL (2018). Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. Res Rep Urol, 10, 205-217. ()
67. Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL (2018). p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 21(2), 260-268. ()
68. Gill DM, Hahn AW, Hale P, Maughan BL (2018). Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Treat Options Oncol, 19(1), 6. ()
69. Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL (2018). p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 10.1038(s41391-017).
70. Hahn AW, Gill DM, Agarwal N, Maughan BL (2017). PD-1 checkpoint inhibition: toxicities and management. Urol Oncol, 10.1016(35(12)), 701-701.
71. Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N (2017). Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clin Genitourin Cancer, S1558-7673(10.1016/j.).
72. Terada N, Maughan BL, Akamatsu S, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Antonarakis ES (2017). Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. Int J Urol, 24(6), 441-448. ()
73. Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW (2017). The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate, 77(13)(10.1002/pr), 1303-1311.
74. Maughan BL, Luber B, Nadal R, Antonarakis ES (2017). Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. Prostate, 77(1), 33-40. ()
75. Maughan BL, Suzman DL, Luber B, Wang H, Glavaris S, Hughes R, Sullivan R, Harb R, Boudadi K, Paller C, Eisenberger M, Demarzo A, Ross A, Antonarakis ES (2016). Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol, 78(6), 1297-1304. ()
76. Maughan BL, Antonarakis ES (2015). Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Curr Treat Options Oncol, 16(12), 57. ()
77. Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES (2015). Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Prostate, 75(15), 1814-20. ()
78. Maughan BL, Antonarakis ES (2014). Enzalutamide in chemo-naive castration-resistant prostate cancer: effective for most but not for all. Asian J Androl, 16(6), 807-8. ()
79. Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G (2014). Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 12(2), 130-7. ()
80. Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (2013). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 11(3), 316-20. ()
81. Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N (2013). Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer, 2013, 981684. ()

Review

1. Gebrael G, Sahu KK, Agarwal N, Maughan BL (2023). Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. [Review]. Hum Vaccin Immunother, 19(1), 2193528. ()
2. Maughan BL, Sirohi D (2023). Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials. [Review]. Curr Treat Options Oncol, 24(9), 1199-1212. ()
3. Li H, Sahu KK, Maughan BL (2022). Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. [Review]. Cancers (Basel), 14(10). ()
4. Maughan BL (2022). Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022. [Review]. Curr Oncol Rep, 24, 1201-1208. ()
5. Maughan BL, Antonarakis ES (2015). Androgen pathway resistance in prostate cancer and therapeutic implications. [Review]. Expert Opin Pharmacother, 16(10), 1521-37. ()

Case Report

1. McComas K, Agarwal N, Bowen G, Maughan BL, Tward JD (2020). Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clin Genitourin Cancer, 18(5), e573-e584. ()

Editorial

1. Galarza Fortuna GM, Maughan BL (2024). The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the modern era. Transl Androl Urol, 13(5), 915-919. ()
2. Rathi N, Maughan BL, Agarwal N, Swami U (2019). The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. Transl Cancer Res, 8(8), E1-E6. ()
3. Maughan BL, Eisenberger MA (2016). A Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks? Eur Urol, 70(5), 732-733. ()

Letter

1. Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N (2019). Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. [Letter to the editor]. J Geriatr Oncol, 11(4), 724-726. ()

Abstract

1. P Twardowski, J YCWong, SKPal, B LMaughan, P H Frankel, K Franklin, M Junqueira, M RPrajapati, G Nachaegari, D Harwood, N Agarwal (12/28/2018). Randomized phase II trial of Sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer [Abstract]. Cancer Treatment and Research Communications (doi: 10.1016/j.ctarc.2018.100116), 20 December 2018, 100116.
2. Sirohi D, Smith SC, Agarwal N, Maughan BL (November 2018). Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities [Abstract]. Dove Medical Press, 2018(10), 205-217.
3. Maughan BL, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES (2015). Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) [Abstract]. J Clin Oncol, 33(Suppl 7), abstr 252.

Other

1. Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N (2023). Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. Prostate Cancer Prostatic Dis. England. ()
2. Maughan BL (2021). Combination therapy with radium-223 and enzalutamide in castration-resistant prostate cancer. Clin Adv Hematol Oncol (19(12), pp. 764-766). United States. ()

Huntsman Cancer Institute News

• Ask an Expert: Kidney Cancer
• Translational Scholar: Benjamin L. Maughan, MD, PharmD
• Chasing—and Catching—His Dreams